Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

Novavax, Inc. (NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The FDA approved Moderna’s new Covid-19 vaccine late Friday, though it placed restrictions on its use that the company’s ...

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

(Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach ...

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing ...